Ron Leuty

An upsized $332 million offering is the latest Bay Area biotech IPO — and the company is just three years old.

An S.F. startup plans to turn $115 million into a new kind of treatment for a deadly disease. Find out about the Goldman Sachs veteran leading the charge.

Braveheart Bio raised $382.5M in its IPO, pricing shares at $18. The San Francisco biotech is developing a drug for hypertrophic cardiomyopathy.

Here's how much lawyers will earn from suits around 23andMe's 2023 data breach.

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of cutting-edge pancreatic cancer drug

ReCode Therapeutics CEO exits for chairman role as it brings in new money, new direction

Amber Salzman has seen a rare, inherited muscle disorder devastate her family. Now, with a fresh $90 million supply of cash, her South San Francisco company is closer to doing something about it.

Many startups raise seed money from VCs and don't go on to get any more investment. Here's how one Alameda company beat the odds.

Here are the two big winners for bankrupt Sangamo Therapeutics' assets.

Heart attack: A Bay Area company is suing giant Bristol-Myers Squibb to protect an important cardiac drug.